The addition of PDGF (5 ng/ml) induced an increase in 3H-thymidine incorporation 
Introduction
Advanced glycation end-products (AGEs), which result from non-enzymatic glycation of proteins, are thought to contribute to the development of diabetic complications, including macro-and micro-angiopathies (1, 2). However, the interaction of glucose with proteins in vivo is not restricted to diabetic patients (3-5). We have shown that AGE-modified collagen increased in the aorta of nondiabetic subjects with age (6). A recent study in individuals suffering from hyperlipidemia showed that glycated LDL was susceptible to oxidation and increased complex formation with matrix proteins (7). Thus, non-enzymatic glycation of proteins, including collagen and LDL, may play a role in the development of human atherosclerotic lesions. However, the detailed mechanism by which AGEs accelerate atherosclerosis has not been elucidated.
Recent studies have focused on the ligand activity of 
Results
Characterization of AGE-BSA The intensity of the Maillard reaction-related fluorescence (units/mg) of samples was expressed as their fluorescence subtracted from background fluorescence. AGE-BSA solution (1,351.6 units/mg) exhibited a significantly higher fluorescence than unmod-BSA solution (17.1 units/mg) or freshly prepared BSA solution (6.9 units/mg). Figure 1 shows the inhibition curves of AGE-BSA, unmod-BSA and freshly prepared BSA by a competitive ELISA assay using monoclonal anti-CML antibody. The monoclonal anti-CML antibody reacted with AGE-BSA, but not with freshly prepared BSA. Unmod-BSA reacted weakly with monoclonal anti-CML antibody. However, the mean CML content of AGE-BSA solution was 66-fold greater than that of unmod-BSA solution.
MTT assay Figure 2 shows the mean values of optical density (A570) of SMCs at two and four days after incubation with various concentrations of AGE-BSA or unmod-BSA.
No difference in the optical density of SMCs was observed between AGE-BSA and unmod-BSA at two days. At four days, the optical density of SMCs in AGE-BSA was similar to that in unmod-BSA at concentrations of up to 20 
Discussion
Recent in vivo studies (6 , 15, 16) have reported the presence of AGE-protein adducts in atherosclerotic lesions and diabetic glomerulosclerosis . AGEs possess ligand activity for several specific surface receptors on various cells, which modulate various cellular functions , including migration and proliferation (8, 9) . Yui et al. (9) showed that the growth of murine macrophages was induced by AGE-modified proteins. Conversely, AGEmodified matrix has been shown to inhibit the proliferative activity of cultured mesangial cells (17 , 18) . The effect of AGE-modified proteins on the proliferative activity of SMCs remains controversial (10, 11). Since atherosclerotic lesions are caused by proliferation of vascular SMCs , we were interested in the effect of AGE-modified proteins on the proliferative activity of SMCs. In this study , MTT analysis showed that the optical density (A570) of SMCs was similar between AGE-BSA and unmod-BSA at con- The biological role of increased SMC fibronectin production due to AGE-modified proteins in atherogenesis cannot be elucidated from this study. Fibronectin is known to be a pericellular matrix glycoprotein, which interacts with cells and other matrix components.
There have been reports (31, 32) that fibronectin accumulates in early lesions induced by mechanical injuries or atherogenic diets. Recently, SMCs obtained from hypercholesterolemic animals have been shown to have elevated expression of fibronectin mRNA and fibronectin synthesis (33, 34). We previously showed that AGE-adducts increased in the collagen matrix of lesion-free intima in non-diabetic subjects with age (6). Thus, AGE-adducts may play a role in atherogenesis by enhancing fibronectin production by SMCs. 
